Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol + oxytocin versus oxytocin alone for blood loss control during elective caesarean section
PACTR202310568262804Completed
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Trial of misoprostol and oxytocin in postpartum hemorrhage (PPH) (2 arms). Primary endpoint: Blood loss. Started Jun 2022; status: completed.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202310568262804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202310568262804.